慢性肺曲霉菌病的治疗现状及展望  

Current situation and future perspectives of treatment of chronic pulmonary aspergillosis

作　　者：王娜娜[1] 谭效锋[1] 马涛[2] 程玉生[3] WANG Nana;TAN Xiaofeng;MA Tao;CHENG Yusheng(Department of General Internal Medicine,Tianjin Hospital,Tianjin 200040,China;Department of Hand and Foot Surgery,Yijishan Hospital of Wannan Medical College,Wuhu 241001,Anhui,China;Department of Respiratory Medicine,Yijishan Hospital of Wannan Medical College,Wuhu 241001,Anhui,China)

机构地区：[1]天津市天津医院普内科,天津200040 [2]皖南医学院弋矶山医院手足踝外科,安徽芜湖241001 [3]皖南医学院弋矶山医院呼吸与危重症医学科,安徽芜湖241001

出　　处：《中国临床药理学与治疗学》2021年第2期217-222,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金(81301605);芜湖市科技攻关项目(2020dx1-3)。

摘　　要：慢性肺曲霉菌病(chronic pulmonary aspergillosis,CPA)是一种严重的肺部真菌感染性疾病,常导致肺结核、慢性阻塞性肺疾病和结节病等疾病复杂化,病死率高。目前,CPA的治疗策略主要包括药物治疗与手术治疗,治疗方案的选择应综合患者所患CPA的种类、临床表现和有无外科手术适应症等情况来决定。然而,迄今为止,临床实践中仍缺乏治疗CPA的标准方案。本文拟综述近年来CPA治疗领域的最新研究成果,总结CPA的治疗现状及进展。Chronic pulmonary aspergillosis(CPA)is a serious fungal infection,which complicates pulmonary tuberculosis,chronic obstructive pulmonary disease and sarcoidosis with high mortality.At present,the treatment of CPA include drug treatment and surgical treatment.The treatment plan should be determined by the type,clinical manifestations and surgical indications of the patients.Nevertheless,there is no standard plan,and more research is needed to improve it.Combined with the current literature reports,this article reviews the current and progress in the treatment of CPA.

关 键 词：慢性肺曲霉菌病 抗真菌治疗 文献综述 

分 类 号：R518[医药卫生—内科学] R56[医药卫生—临床医学]